Female fertility preservation Innovations and questions

Capsule:
Preserving the potential of becoming genetic mother should now be part of the management of infants, adolescents, and young women at risk for infertility from benign or malignant diseases.

Authors:
René Frydman, M.D., Ph.D., Michaël Grynberg, M.D., Ph.D.

Volume 105, Issue 1, Pages 4-5

Abstract:

Oocyte and ovarian tissue cryopreservation represents one of the most important advances in the field of reproductive medicine and biology. Preserving a woman’s potential for becoming a genetic mother is now possible for numerous diseases that could impair female fertility either by themselves or as a result of their treatment. However, female fertility preservation is still at the pioneering level and is thus often considered an experimental treatment either from a technical standpoint or in the clinical situation in which it is discussed. As a consequence, many ethics issues are raised with fertility preservation treatment in infants, adolescents, and young women.

Translate »